Inhibition of HIF-la activity is a novel strategy for the treatment of tubulointerstitial fibrosis

抑制HIF-1α活性是治疗肾小管间质纤维化的新策略

基本信息

  • 批准号:
    17590839
  • 负责人:
  • 金额:
    $ 2.37万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

Chronic hypoxia is a main contributor to the progression of tubulointerstitial fibrosis. In this study, we investigated the extent to which hypoxia-inducible factor 1α (HIF-1α) mediates epithelial-mesenchymal-transition (EMT) in vivo and in vitro using a mouse model in which renal proximal epithelial HIF-1α expression was selectively deleted and assessed the role of HIF-1α in EMT-mediated renal fibrosis. In addition, we developed a method with which to detect EMT in vitro, using Cre-recombinase activated β-galactosidase (LacZ) to identify and track primary tubular epithelial cells (TECs). To determine whether HIF-la is involved in the development of tubulointerstitial fibrosis in vivo, renal fibrosis was induced by unilateral urethral obstruction (UUO) in HIF-la-mutant and wild-type mice. Kidneys were harvested for immunohistochemistry 8 days after UUO and stained for FSP1 (fibroblast-specific protein 1, a marker for EMT) using a modified ABC-peroxidase method. Numbers of FSP1+ cells w … More ere significantly lower in obstructed kidneys from HIF-1α-mutant than wild type mice. Moreover, after exposure to hypoxia (1% O_2), but not normoxia (20.9% O_2), for 5 days cultured TECs permanently marked with LacZ assumed a fibroblast-like morphology. And double staining for LacZ and FSP1 revealed that whereas 8.2% of TECs underwent EMT (LacZ+/FSP1+) under normoxic conditions, 28.3% underwent EMT under hypoxic conditions. We also determined that blockade of HIF-1α activity can be a novel approach for the treatment of tubulointerstitial fibrosis through the inhibition of epithelial-mesenchymal-transition (EMT) in vitro and in vivo, using YC-1(3-(5'-hydroxymethy1-2'-fury1)-1-benzyl indazole) as an anti-HIF-1α agent.Taken together, our results suggest that, through activation of HIF-1, hypoxia plays a key role in the induction of EMT and in EMT-mediated renal fibrosis in vitro and in vivo and anti-HIF-1α agents may be utilized for the treatment of tubulointerstitial fibrosis through the inhibition of EMT. Less
慢性缺氧是肾小管间质纤维化进展的主要原因。在这项研究中,我们研究了缺氧诱导因子1α(HIF-1α)在体内和体外介导上皮间质转化(EMT)的程度,使用小鼠模型,其中肾近端上皮HIF-1α表达被选择性删除,并评估HIF-1α在EMT介导的肾纤维化中的作用。此外,我们开发了一种体外检测EMT的方法,使用Cre重组酶激活的β-半乳糖苷酶(LacZ)来识别和跟踪原代肾小管上皮细胞(TEC)。为了确定HIF-Ia是否参与体内肾小管间质纤维化的发展,在HIF-Ia突变型和野生型小鼠中通过单侧尿道梗阻(UUO)诱导肾纤维化。在UUO后8天收获肾脏用于免疫组织化学,并使用改良的ABC-过氧化物酶法对FSP 1(成纤维细胞特异性蛋白1,EMT的标志物)进行染色。FSP 1+细胞数量 ...更多信息 HIF-1α突变体小鼠梗阻肾中HIF-1 α的表达显著低于野生型小鼠。此外,在缺氧(1%O_2)而非常氧(20.9%O_2)条件下,培养的TECs经LacZ永久标记5天后呈现成纤维细胞样形态。LacZ和FSP 1双染显示,在常氧条件下,8.2%的TEC发生EMT(LacZ+/FSP 1+),而在低氧条件下,28.3%的TEC发生EMT。我们还确定,阻断HIF-1α活性可能是一种新的治疗肾小管间质纤维化的方法,通过抑制上皮间质转化(EMT),在体外和体内,使用YC-1(3-(5 '-羟甲基-2'-呋喃基)-1-苄基吲唑)作为抗HIF-1α剂。总之,我们的结果表明,通过激活HIF-1,缺氧在体外和体内诱导EMT和EMT介导的肾纤维化中起关键作用,抗HIF-1α药物可通过抑制EMT用于治疗肾小管间质纤维化。少

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Annual Review 2007 腎臓
2007 年肾脏年度回顾
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    田中;宏樹;平田 拓
  • 通讯作者:
    平田 拓
Fibroblast-specific protein 1 is a specific marker for renal survival in patients with IgAN
成纤维细胞特异性蛋白 1 是 IgAN 患者肾脏存活的特异性标志物
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Naruse M;Sakaguchi S;Nakayama Y;Nonoguchi H;Tomita K;Nishitani Y
  • 通讯作者:
    Nishitani Y
FSP 1 as a marker for renal survival
FSP 1 作为肾脏存活的标志物
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Muto;S.;et al.;Iwano M
  • 通讯作者:
    Iwano M
間質線維化の発症機序と治療戦略
间质纤维化的发病机制及治疗策略
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Matsushima;Y.;et al.;岩野正之
  • 通讯作者:
    岩野正之
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IWANO Masayuki其他文献

IWANO Masayuki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IWANO Masayuki', 18)}}的其他基金

Novel strategy for the treatment of active nephritis using secreted FSP1
利用分泌型 FSP1 治疗活动性肾炎的新策略
  • 批准号:
    24390216
  • 财政年份:
    2012
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Protective role of FSP1-positive podocytes in the glomerular injury
FSP1阳性足细胞在肾小球损伤中的保护作用
  • 批准号:
    21591036
  • 财政年份:
    2009
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of podocyte expression of FSP1 in the progression of kidney disease
FSP1 足细胞表达在肾脏疾病进展中的作用
  • 批准号:
    19590960
  • 财政年份:
    2007
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
HIF-1α is a key molecule for the progression of EMT-mediated renal fibrosis
HIF-1α是EMT介导的肾纤维化进展的关键分子
  • 批准号:
    15590854
  • 财政年份:
    2003
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Involvement of FSP1 positive fibroblasts in the progression of human glomerulonephntis
FSP1阳性成纤维细胞参与人肾小球肾炎的进展
  • 批准号:
    12671043
  • 财政年份:
    2000
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Development and Validation of a Deep Learning system to estimate Interstitial Fibrosis from a kidney ultrasonography image
开发和验证从肾脏超声图像估计间质纤维化的深度学习系统
  • 批准号:
    10781840
  • 财政年份:
    2023
  • 资助金额:
    $ 2.37万
  • 项目类别:
Development of new therapeutic strategy against renal interstitial fibrosis utilizing mTOR inhibitor
利用 mTOR 抑制剂开发抗肾间质纤维化的新治疗策略
  • 批准号:
    22K06736
  • 财政年份:
    2022
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Inflammatory Signaling in Kidney Stromal Cells Driving Interstitial Fibrosis
肾基质细胞中的炎症信号驱动间质纤维化
  • 批准号:
    10371183
  • 财政年份:
    2020
  • 资助金额:
    $ 2.37万
  • 项目类别:
Nitric oxide attenuates renal interstitial fibrosis
一氧化氮减轻肾间质纤维化
  • 批准号:
    19K17726
  • 财政年份:
    2019
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Renal interstitial fibrosis in renal venous congestion
肾静脉充血导致肾间质纤维化
  • 批准号:
    19H03677
  • 财政年份:
    2019
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The unbalance between post-inflammatory apoptosis and NETosis possibly effects on the phagocyte which accelerate interstitial fibrosis in kidney
炎症后细胞凋亡与NETosis失衡可能影响吞噬细胞,加速肾间质纤维化
  • 批准号:
    18K08217
  • 财政年份:
    2018
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Preventing and Reversing Interstitial Fibrosis in HFpEF
预防和逆转 HFpEF 的间质纤维化
  • 批准号:
    10232045
  • 财政年份:
    2016
  • 资助金额:
    $ 2.37万
  • 项目类别:
Preventing and Reversing Interstitial Fibrosis in HFpEF
预防和逆转 HFpEF 的间质纤维化
  • 批准号:
    10015539
  • 财政年份:
    2016
  • 资助金额:
    $ 2.37万
  • 项目类别:
Influence of tacrolimus initial doing strategy based on the CYP3A5 polymorphisms on quantitative interstitial fibrosis, rejection rate, and long-term graft function in kidney transplant recipients.
基于CYP3A5多态性的他克莫司初始治疗策略对肾移植受者定量间质纤维化、排斥率和长期移植物功能的影响。
  • 批准号:
    15K10636
  • 财政年份:
    2015
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Diabetic Heart Disease – From Left Ventricular Intramyocardial Triglyceride Accumulation to Diffuse Interstitial Fibrosis and Myocardial Dysfunction
糖尿病性心脏病 — 从左心室心肌内甘油三酯蓄积到弥漫性间质纤维化和心肌功能障碍
  • 批准号:
    nhmrc : 1054581
  • 财政年份:
    2013
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Early Career Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了